alpha-aminopyridine has been researched along with Cholangiocellular Carcinoma in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Ducreux, M; Facchinetti, F; Friboulet, L; Hollebecque, A; Malka, D; Valery, M | 1 |
Chen, MH; Chen, YY; Cheng, CT; Chiang, KC; Tsai, CY; Wu, RC; Yeh, CN; Yeh, TS | 1 |
2 other study(ies) available for alpha-aminopyridine and Cholangiocellular Carcinoma
Article | Year |
---|---|
Cholangiocarcinoma with STRN-ALK translocation treated with ALK inhibitors.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Bile Duct Neoplasms; Calmodulin-Binding Proteins; Cholangiocarcinoma; Female; Humans; Lactams; Membrane Proteins; Nerve Tissue Proteins; Pyrazoles; Receptor Protein-Tyrosine Kinases; Translocation, Genetic | 2021 |
MET‑RON dual inhibitor, BMS‑777607, suppresses cholangiocarcinoma cell growth, and MET‑RON upregulation indicates worse prognosis for intra‑hepatic cholangiocarcinoma patients.
Topics: Aminopyridines; Animals; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers, Tumor; Cell Proliferation; Cholangiocarcinoma; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Prognosis; Proto-Oncogene Proteins c-met; Pyridones; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Tumor Cells, Cultured | 2018 |